Juel Jacob
Department of Plastic Surgery, Aalborg University Hospital, Aalborg, Denmark.
Case Rep Gastrointest Med. 2017;2017:8905372. doi: 10.1155/2017/8905372. Epub 2017 Oct 4.
Gastroesophageal reflux disease (GORD) is an often debilitating condition characterised by retrograde flow of content from stomach into the oesophagus, where the low pH of the stomach acid irritates the mucosa of the oesophagus. The most dominant symptoms in GORD are pyrosis, regurgitation, and dysphagia. Sublingual immunotherapy (SLIT) was first described in 1986. Following this description, the use has greatly increased in the treatment of allergic rhinitis, as an alternative to subcutaneously administered immunotherapy. Side effects are commonly of oropharyngeal and gastrointestinal nature, for example, swelling, itching, irritation, ulceration of the oropharynx and nausea, abdominal pain, vomiting, and diarrhoea. More serious side effects are dominated by respiratory tract and systemic manifestations. A 30-year-old male experienced refractory, relentless, and debilitation GORD subsequent to administration of sublingual immunotherapy for house dust mite in allergic rhinitis. The patient had to stop the SLIT after two weeks of administration due to GORD. The cessation resulted in rapid resolution of symptoms.
胃食管反流病（GORD）是一种常使人衰弱的病症，其特征是胃内容物逆向流入食管，胃酸的低pH值会刺激食管黏膜。GORD最主要的症状是烧心、反流和吞咽困难。舌下免疫疗法（SLIT）于1986年首次被描述。在此描述之后，其在过敏性鼻炎治疗中的应用大幅增加，作为皮下注射免疫疗法的替代方法。副作用通常具有口咽和胃肠道性质，例如口咽肿胀、瘙痒、刺激、溃疡以及恶心、腹痛、呕吐和腹泻。更严重的副作用主要是呼吸道和全身表现。一名30岁男性在接受舌下免疫疗法治疗过敏性鼻炎中的屋尘螨后，出现了难治性、持续性且使人衰弱的GORD。该患者在给药两周后因GORD不得不停止SLIT。停止治疗后症状迅速缓解。
